When the laboratory does not receive the information on CLL cell content and routine CD19+ cell separation is not doable due to cost/time expenses, the laboratory should employ separation of mononuclear cells and inform the clinician in the report that the result should be interpreted with respect to tumor cells content in the provided sample. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.